NNP:多西环素治疗神经性莱姆病,一项多中心、双盲、随机和安慰剂对照试验

2022-08-23 网络 网络

神经型莱姆病(LNB)通常表现为疼痛性脑膜神经根炎和/或颅神经炎,并伴有不适和疲劳。更罕见的临床表现是丛神经炎、单神经炎和中枢神经系统(CNS)综合征,如脊髓炎、血管炎和脑炎。LNB患者应尽快使用抗生

神经型莱姆病(LNB)通常表现为疼痛性脑膜神经根炎和/或颅神经炎,并伴有不适和疲劳。更罕见的临床表现是丛神经炎、单神经炎和中枢神经系统(CNS)综合征,如脊髓炎、血管炎和脑炎。LNB患者应尽快使用抗生素治疗,但抗生素类型的选择和治疗时间都是讨论的问题。静脉注射β-内酰胺类抗生素(青霉素G、头孢曲松和头孢噻肟)和口服强力霉素被证明是有效的,并保持相对良好的脑脊液(CSF)渗透性。口服多西环素治疗典型的LNB并不比静脉注射头孢曲松差,并且可能对主要累及中枢神经系统的LNBs有效。根据这一知识,欧洲神经学会联合会(EFNS)2015年的指南建议成人使用β-内酰胺抗生素或强力霉素进行治疗。抗生素类型的最终选择取决于个体因素,如年龄、耐受性、妊娠、母乳喂养和首选给药方式。根据指南,脑炎、脊髓炎或血管炎患者应静脉注射头孢曲松。

关于治疗时间的建议存在分歧。之前只有一项随机试验比较了播散性莱姆病的治疗时间。在该试验中,包括62例明确LNB和53例可能LNB,治疗3个月的患者的长期结果没有差异 与接受治疗的患者相比,静脉注射头孢曲松3周 静脉注射头孢曲松2周,然后注射阿莫西林100天。同样值得注意的是,有几项研究评估了所谓的莱姆病后患者的长期抗生素治疗,但没有证明其益处。本文旨在比较口服强力霉素治疗和的疗效和安全性 在一项随机对照试验中,在欧洲LNB进行了数周的研究。选择了非劣效性方法来评估疗效,因为短期抗生素方案预计不会优于长期方案,但它在抗生素耐药性问题、较低成本和患者压力较小方面仍具有明显优势。本文发表在《神经病学,神经外科学和精神病学杂志》上()。

该试验采用随机、双盲、安慰剂对照。从挪威八家医院招募LNB患者,随机分为多西环素200组 mg,每日一次,持续2周 ,然后是4周安慰剂或强力霉素200 mg,每日一次,共6周 。主要终点是临床改善,通过基线的综合临床评分(0-64分)的差异来衡量。16名患者在10周时进行了门诊随访, 并在第2个月和第4个月收集额外的血样 治疗开始后的数周。在每次就诊时对患者进行综合临床评分(CCS)。CSS测量了10种主观症状和22种客观神经学发现。32项中的每项得分为0=无,1=轻度(不影响日常生活)或2=重度(影响日常生活),总分范围从0到64.16,每个地点的临床医生为患者评分,必要时与研究协调员讨论。

研究流程

次要终点为10周和12个月时的CCS、6个月和12个月中的CSF结果、2个月和4个月时通过血液测试(血液学值、肾和肝功能)测量的安全性和耐受性 治疗开始数周后,患者在10周的患者日记中报告结果指标(PROM)和每周报告的副作用。PROM采用疲劳严重程度量表进行疲劳评分,采用患者健康问卷-15进行主观躯体症状评分,并采用健康相关生活质量(RAND 36)。患者日记包括五个关于副作用的问题;恶心、腹泻、皮肤变化、生殖器疾病和食欲下降。每个问题的答案为0=无症状,1=轻度症状或2=严重症状,每周计算总分,范围从0到10。

两个治疗组在整个研究过程中的综合临床评分

共纳入121名患者。52例治疗2周 ,53例治疗6周。只有一名患者确诊为LNB-CNS综合征,并伴有脊髓炎的临床和放射学体征。13名患者(2名患者中7名 治疗组6周,对照组6周 周治疗组)的得分可指示中枢神经系统受累。然而,这些发现很细微,大多数评分为轻度,没有一个得到MRI的证实。在任何时间点,治疗组之间的中位数和得分均无差异。治疗组之间唯一不同的问题是在第5周出现恶心,其中6周治疗组有9名患者出现轻度恶心,2周治疗组只有3名患者出现轻微恶心。服用6 周以上多西环素没有任何益处 治疗组在第10周和第12周的临床评分等次要结果方面没有差异 。脑脊液数据和患者报告了疲劳、主观躯体症状评分和健康相关生活质量的结果。其次,我们在两组中均未发现任何治疗失败。绝大多数患者改善良好。没有记录任何与治疗相关的严重不良事件。

结果表明,多西环素治疗在超过2周后没有任何益处。

Solheim AMLorentzen ÅRDahlberg AO, et al Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2023-03-30 amyloid
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-20 xlxchina
  9. [GetPortalCommentsPageByObjectIdResponse(id=1987345, encodeId=56c0198e34500, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Apr 07 14:50:45 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904146, encodeId=281b1904146a9, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Sep 24 05:50:45 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035508, encodeId=53172035508d1, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Sep 30 16:50:45 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775663, encodeId=a5e61e75663aa, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Mar 30 21:50:45 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304435, encodeId=bc111304435db, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370607, encodeId=e49f13e06078a, content=<a href='/topic/show?id=cca84345545' target=_blank style='color:#2F92EE;'>#多西环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43455, encryptionId=cca84345545, topicName=多西环素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439063, encodeId=4b5914390635d, content=<a href='/topic/show?id=5fef8e995c7' target=_blank style='color:#2F92EE;'>#莱姆病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87995, encryptionId=5fef8e995c7, topicName=莱姆病)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573137, encodeId=e0f015e3137c2, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585590, encodeId=9594158559021, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Sat Aug 20 13:50:45 CST 2022, time=2022-08-20, status=1, ipAttribution=)]

相关资讯

JAMA:多西环素不能减缓腹主动脉瘤的生长速度

研究认为,在小肾下腹主动脉瘤患者中,多西环素与安慰剂相比,在2年内没有显著减缓动脉瘤的生长速率,不支持使用多西环素来减缓小腹主动脉瘤的生长

J Dermatolog Treat:多西环素治疗早期真菌病的疗效

蕈样真菌病(MF)是原发性皮肤T细胞淋巴瘤(CTCLs)的最常见形式。多西环素是四环素类抗生素中的一种,能促进不同人类恶性细胞系和体内模型的细胞凋亡。

多西环素和米诺环素的区别及临床新用途

四环素类抗菌药物属于广谱抑菌性抗生素,通过与细菌核糖体30S亚基结合,抑制蛋白质合成发挥抗菌作用。目前,临床常用的四环素类抗生素为多西环素和米诺环素。

Braz Oral Res:多西环素封装在β-环糊精中可用于治疗牙周炎

该临床试验比较了β-环糊精(DOX)/βCD)中的多西环素(DOX)与DOX-单用凝胶对33名牙周炎受试者的疗效。

BMC Infect Dis:治疗幽门螺杆菌感染,多西环素VS.左氧氟沙星的疗效

抗生素耐药性降低了全世界幽门螺杆菌感染的传统三联疗法的疗效,这就需要使用各种治疗方案。一项开放标签、随机、平行、优势的临床试验使用了两种方案,基于多西环素的四联疗法和同时使用左氧氟沙星的方案,旨在评估

NEJM:多西环素治疗方案用于男男同性恋人群直肠衣原体感染

在直肠衣原体感染的男性同性恋人群中,7天的多西环素治疗方案在微生物学治愈率方面优于阿奇霉素方案

拓展阅读

Aging:这两种常见的抗生素,竟能大幅延长寿命

研究显示,两种常见的抗生素多西环素、阿奇霉素,单独或两者组合治疗线虫,可以显著延长线虫的寿命,表明线粒体抑制剂具有消除衰老的作用。

NEJM:多西环素可以减少三分之二的性传播感染

使用多西环素接触后预防的淋病、衣原体和梅毒的综合发病率比使用标准护理低2/3。

Lancet Infect Dis:多西环素7天VS.14天治疗游走性红斑的疗效

莱姆病是欧洲和美国最流行的病媒传播疾病。多西环素治疗10天是红斑移行症的主要治疗建议。

J Dermatolog Treat:多西环素治疗早期真菌病的疗效

蕈样真菌病(MF)是原发性皮肤T细胞淋巴瘤(CTCLs)的最常见形式。多西环素是四环素类抗生素中的一种,能促进不同人类恶性细胞系和体内模型的细胞凋亡。

BMC Infect Dis:治疗幽门螺杆菌感染,多西环素VS.左氧氟沙星的疗效

抗生素耐药性降低了全世界幽门螺杆菌感染的传统三联疗法的疗效,这就需要使用各种治疗方案。一项开放标签、随机、平行、优势的临床试验使用了两种方案,基于多西环素的四联疗法和同时使用左氧氟沙星的方案,旨在评估

NEJM:多西环素治疗方案用于男男同性恋人群直肠衣原体感染

在直肠衣原体感染的男性同性恋人群中,7天的多西环素治疗方案在微生物学治愈率方面优于阿奇霉素方案